ReviewDrugs in context2026

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications.

Mario Manunta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.